Sentences with phrase «efficacy of our programs in»

I've seen the potential for districts to gather local evidence on the efficacy of their programs in this way through the Proving Ground project at the Center for Education Policy Research (CEPR) at Harvard University, where I am director.

As a leader in the field of social - emotional learning, we take part in international conferences focused on education policy and reform and collaborate with research organizations to study the viability and efficacy of our programs in individual countries.

Not exact matches

Topics included: early reporting on inaccuracies in the articles of The New York Times's Judith Miller that built support for the invasion of Iraq; the media campaign to destroy UN chief Kofi Annan and undermine confidence in multilateral solutions; revelations by George Bush's biographer that as far back as 1999 then - presidential candidate Bush already spoke of wanting to invade Iraq; the real reason Bush was grounded during his National Guard days — as recounted by the widow of the pilot who replaced him; an article published throughout the world that highlighted the West's lack of resolve to seriously pursue the genocidal fugitive Bosnian Serb leader Radovan Karadzic, responsible for the largest number of European civilian deaths since World War II; several investigations of allegations by former members concerning the practices of Scientology; corruption in the leadership of the nation's largest police union; a well - connected humanitarian relief organization operating as a cover for unauthorized US covert intervention abroad; detailed evidence that a powerful congressional critic of Bill Clinton and Al Gore for financial irregularities and personal improprieties had his own track record of far more serious transgressions; a look at the practices and values of top Democratic operative and the clients they represent when out of power in Washington; the murky international interests that fueled both George W. Bush's and Hillary Clinton's presidential campaigns; the efficacy of various proposed solutions to the failed war on drugs; the poor - quality televised news program for teens (with lots of advertising) that has quietly seeped into many of America's public schools; an early exploration of deceptive practices by the credit card industry; a study of ecosystem destruction in Irian Jaya, one of the world's last substantial rain forests.

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (tprograms; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (tPrograms (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (tprograms; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

Most biotechs would have shuttered a clinical program that showed absolutely no efficacy whatsoever in a late - stage trial, but Novavax has instead doubled down on RSV by going forth with its phase 3 trial of the RSV F vaccine for infants via maternal immunization, and begun planning for another trial in older adults that's reportedly on track to kick off in 2018.

The award program, created fifteen years ago, rewards and recognizes companies that are investing in rigorous and measurable scientific studies to show the efficacy of their proprietary ingredients, products or technologies.

I think this Salon article makes an interesting point in exploring the efficacy of bystander education programs that target specific communities.

In the third trial of the nurse home visitor program, nurse - visited, 6 - month - old infants born to mothers with low psychological resources (i.e., maternal IQ, mental health, and sense of efficacy) displayed fewer aberrant emotional expressions (e.g., low levels of affect and lack of social referencing of mother) associated with child maltreatment.18

The brief includes the analysis of survey data from program participants on child safety in the home, observed parenting practices, parental stress and parenting efficacy, self - reported parenting practices, and rates of child maltreatment.

Meta - analyses of this expanded research base confirm the model's impacts on a range of risk and protective factors associated with child maltreatment.7, 8,9 In addition, all of the major home visitation models in the U.S. are currently engaged in a variety of research activities, many of which are resulting in better defined models and more rigorous attention to the key issue of participant enrolment and retention, staff training and quality assurance standards.10 For example, recent findings emerging from the initial two - year follow - up of the Early Head Start National Demonstration Project confirm the efficacy of home visitation programs with new parentIn addition, all of the major home visitation models in the U.S. are currently engaged in a variety of research activities, many of which are resulting in better defined models and more rigorous attention to the key issue of participant enrolment and retention, staff training and quality assurance standards.10 For example, recent findings emerging from the initial two - year follow - up of the Early Head Start National Demonstration Project confirm the efficacy of home visitation programs with new parentin the U.S. are currently engaged in a variety of research activities, many of which are resulting in better defined models and more rigorous attention to the key issue of participant enrolment and retention, staff training and quality assurance standards.10 For example, recent findings emerging from the initial two - year follow - up of the Early Head Start National Demonstration Project confirm the efficacy of home visitation programs with new parentin a variety of research activities, many of which are resulting in better defined models and more rigorous attention to the key issue of participant enrolment and retention, staff training and quality assurance standards.10 For example, recent findings emerging from the initial two - year follow - up of the Early Head Start National Demonstration Project confirm the efficacy of home visitation programs with new parentin better defined models and more rigorous attention to the key issue of participant enrolment and retention, staff training and quality assurance standards.10 For example, recent findings emerging from the initial two - year follow - up of the Early Head Start National Demonstration Project confirm the efficacy of home visitation programs with new parents.

In addition to being influenced by the outcome of interest, the efficacy of home visiting programs is dependent upon the population targeted, providers and home visit content.

In order to accurately measure the efficacy of several home visiting programs, a comprehensive assessment that includes measures of multiple child and family outcomes at various points in time should be favoureIn order to accurately measure the efficacy of several home visiting programs, a comprehensive assessment that includes measures of multiple child and family outcomes at various points in time should be favourein time should be favoured.

Personally I am not a fan of these types of structured programs because 1) there is not adequate research to support their efficacy and 2) they approach literacy development in a highly contrived manner.

Meta - analyses of studies evaluating these programs show positive effects on the competence, efficacy and psychological health of the parents, as well as on the behaviour of the children.49, 50 A recent implementation study of a strategy for parenting and family support showed that families in the treatment group had far fewer cases of substantiated child maltreatment, abuse injuries and out - of - home placements.51

In the teaching of research ethics, she initiated the Teaching Responsible Conduct of Research (TRCR) certificate program offered through the University of Illinois and done research on the efficacy of and developed materials in wide use, including experiential learning materials ranging from two - minute challenges for incorporation into substantive courses to role playing exerciseIn the teaching of research ethics, she initiated the Teaching Responsible Conduct of Research (TRCR) certificate program offered through the University of Illinois and done research on the efficacy of and developed materials in wide use, including experiential learning materials ranging from two - minute challenges for incorporation into substantive courses to role playing exercisein wide use, including experiential learning materials ranging from two - minute challenges for incorporation into substantive courses to role playing exercises.

Most studies evaluating the efficacy of AA are not definitive; for the most part, they associate the duration of participation with success in quitting drinking but do not show that the program caused that outcome.

And if it somehow did, Africa is much better equipped to deal with than it was in the 1980s when chloroquine resistance hit, WHO experts say, with strong national malaria programs in place and increased monitoring of drug efficacy.

The program works by connecting computer - generated drug profiles — including mechanisms of action, clinical efficacy, and side effects — with information about how a molecule may interact with human proteins in specific diseases, such as ovarian cancer.

During the past year alone, concerns about oversight of high - containment laboratories; vetting of personnel (personnel reliability); the efficacy of security measures in place for the select agent program; medical countermeasure research, development and distribution; bioterrorism and pandemic influenza preparedness; misuse of beneficial biological research and technologies; and microbial forensics have generated several policy evaluations and prompted the development of policy recommendations and legislation.

Following a lapse in such programs, the findings also stress the importance of including specific coping mechanisms and reinforcing a person's self - efficacy, in other words, bolstering their belief in their own ability to reach their goals.

«We are at a point in our research where we have validated the efficacy of this combination treatment approach in preclinical animal models, and we now need to define its safety through toxicology and pharmacology studies,» says Fisher, Thelma Newmeyer Corman Endowed Chair in Cancer Research and co-leader of the Cancer Molecular Genetics research program at VCU Massey, chairman of VCU School of Medicine's Department of Human and Molecular Genetics and director of the VCU Institute of Molecular Medicine.

The language of program evaluators is framed in terms of efficacy: what is the actual outcome of an intervention, compared with the outcome expected from no intervention?

According to Choe's research team, the current «attract - and - kill» approach, once it is successfully implemented in practical pest management programs, could potentially provide maximum control efficacy with reduced amount of insecticides applied in the environment.

«While these results are encouraging, they represent a first step in exploring the efficacy of prospective memory training with the Virtual Week training program,» said Dr. Craik.

Published in the Journal of Psychosocial Oncology, «Development and Initial Evaluation of a Telephone - Delivered Behavioral Activation and Problem - solving Treatment Program to Address Functional Goals of Breast Cancer Survivors,» covers two studies looking at feasibility and potential efficacy.

In the sensitive tumor models, the ability of anti — cytotoxic T lymphocyte — associated protein 4 or anti — programmed cell death 1 therapy to increase vessel perfusion strongly correlated with its antitumor efficacy.

Modulation of Gut Microbiota: A Novel Paradigm of Enhancing the Efficacy of Programmed Death - 1 and Programmed Death Ligand - 1 Blockade Therapy — Yiming Wang — Frontiers in Immunology

«The objective of the Clinical Cell Therapy Program is to develop new methods to regrow heart muscle and blood vessels, and evaluate the efficacy of these methods as an approach to improving heart function in patients with a variety of heart disorders,» said Anthony DeMaria, M.D., director of the Sulpizio Family Cardiovascular Center at UC San Diego.

Along with our nonprofit partners, this program aims to collect, organize, and validate massive amounts of data generated by clinical trials across our global trial network sites in order to generate novel insights into biomarkers for safety and efficacy, novel treatment strategies, and personalization of treatment regimens.

«The ASGCT decision to include a presentation on AST - OPC1 in its Presidential Symposium signifies the ground - breaking nature of our program, and reflects the encouraging efficacy and safety data we have seen to date in patients with severe spinal cord injuries that have been treated with AST - OPC1,» commented Steve Cartt, President and Chief Executive Officer of Asterias.

In the RV144 vaccine trial, led by the U.S. Military HIV Research Program at the Walter Reed Army Institute of Research, the efficacy at 3.5 - years was 31.2 %; however, a higher early effect (60 %) was seen at 12 months.

Cherylynn Marino, Ph.D., a postdoctoral fellow, received $ 198,645 to examine the efficacy of a mindfulness - based cognitive therapy (MBCT) program in children and adolescents with TBI.

Immunologic checkpoint blockade with anti — cytotoxic T - lymphocyte — associated antigen 4 (CTLA - 4) or anti — programmed death 1 (PD - 1) / programmed death ligand 1 (PD - L1) agents seems to have some degree of clinical efficacy in advanced mucosal melanoma, although data are limited to smaller retrospective series or subset analyses of prospective trials.

With our anti-TIGIT antibody program, we saw anti-tumor efficacy and reactivation of T - cells in preclinical models which is encouraging for the potential of this product as a monotherapy

«This finding is consistent with a hypothesis generated out of the follow - up studies to the RV144 HIV vaccine trial in Thailand that showed the first efficacy in humans,» noted COL Nelson Michael, Director of the U.S. Military HIV Research Program at the Walter Reed Army Institute of Research.

Sanjay Gurunathan from Sanofi Pasteur, manufacturer of one of the vaccines used in RV144, said a new partnership of the US National Institute of Allergy and Infectious Diseases, The Bill & Melinda Gates Foundation, HIV Vaccine Trials Network, US Military HIV Research Program (MHRP), and Sanofi Pasteur — known as the Pox Protein Public Private Partnership, or P5 — will aim to increase vaccine efficacy from the 31.2 percent of the RV144 trial to 50 percent.

«ECHO - 203 is part of the broader ECHO clinical development program investigating efficacy and safety of epacadostat as a core component of combination therapy in a broad range of solid tumor types as well as hematological malignancies,» said Naing.

Many of the formulas we use in the clinic have been around for over a thousand year and have a high degree of clinical efficacy The herbal formulas we use in the anti-aging program are classified as tonics in Chinese medicine.

My Master's project looked at the efficacy of a mindful eating - based diabetes prevention program in a primarily Hispanic food pantry population.

In fact, the efficacy of the Atkins program has been documented in at least one other major study, featured in the JAMA (The Journal of the American Medical Association) in 200In fact, the efficacy of the Atkins program has been documented in at least one other major study, featured in the JAMA (The Journal of the American Medical Association) in 200in at least one other major study, featured in the JAMA (The Journal of the American Medical Association) in 200in the JAMA (The Journal of the American Medical Association) in 200in 2007.

In 2010, The University of Texas MD Anderson Cancer Center received more than $ 4.5 million — one of the largest yoga - related grants ever — from the National Institutes of Health's National Cancer Institute to support an ongoing study of the efficacy of yoga as part of a treatment program for women with breast cancer.

At Parsley Health, we suggest that any supplementation be part of a well designed, personalized program executed in coordination with a physician to assure appropriateness, efficacy and, above all, safety.

Short - term safety, tolerability and efficacy of a very low - calorie - ketogenic diet interventional weight loss program versus hypocaloric diet in patients with type 2 diabetes mellitus.

In episode 210, the hosts step into the debate between those that espouse the efficacy of 12 - step programs such as AA and those who assert that there is no proof that such programs are any more effective than traditional medical help.

In Edutopia's integrated studies research review, discover seven key approaches in effective curriculum integration, get our specific recommendations on evidence - based practices and programs, learn about pitfalls to avoid, and dig into an annotated bibliography of studies supporting the efficacy of integrated studies practiceIn Edutopia's integrated studies research review, discover seven key approaches in effective curriculum integration, get our specific recommendations on evidence - based practices and programs, learn about pitfalls to avoid, and dig into an annotated bibliography of studies supporting the efficacy of integrated studies practicein effective curriculum integration, get our specific recommendations on evidence - based practices and programs, learn about pitfalls to avoid, and dig into an annotated bibliography of studies supporting the efficacy of integrated studies practices.

The efficacy of running one - to - one programs in schools is that, through this approach to technology education for students, teachers and families, schools are providing a laboratory of trial and error and figuring out a way to make sense of the fast - changing world of technology.

It is worth pausing to dwell on this fact: there are virtually no data with which to evaluate the efficacy of this program, yet the program has been embraced by two states and by the largest city in the United States.

For instance, when evaluating the efficacy of an online professional development program, an evaluator may randomly select one group of learners to participate in an online program.

In any case, no reputable researcher would rely on a one - year bump in some test scores to judge the efficacy of a new prograIn any case, no reputable researcher would rely on a one - year bump in some test scores to judge the efficacy of a new prograin some test scores to judge the efficacy of a new program.

Because of this converging scientific consensus, the No Child Left Behind Act requires school districts to demonstrate that they are using reading programs that have been tested for their efficacy through scientific studies in order to qualify for federal reading funds.